Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-P Droz

Showing results (261-270 of 278) with videos related to

Pageof 28
Sort By:
Investigational New Drugs|May 4, 2004
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumorsM J A de Jonge, J P Droz, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patientsJ P Droz, X Muracciole, N Mottet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysisJ T Hartmann, L Einhorn, C R Nichols, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2011
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trialA Fléchon, D Pouessel, C Ferlay, et al.
Cancer|April 3, 2001
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcomeC Bokemeyer, J P Droz, A Horwich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)S Culine, P Kerbrat, A Kramar, et al.
Journal of the National Cancer Institute|November 22, 2001
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumorsJ T Hartmann, S D Fossa, C R Nichols, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2014
Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasiaC Even, P Pautier, P Duvillard, et al.
La Nouvelle Presse Medicale|May 30, 1981
[N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)]J Rouesse, T Tursz, T Le Chevalier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variablesJ Beyer, A Kramar, R Mandanas, et al.
Pageof 28

Showing results (261-270 of 278) with videos related to

Sort By:
Pageof 28
Investigational New Drugs|May 4, 2004
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumorsM J A de Jonge, J P Droz, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patientsJ P Droz, X Muracciole, N Mottet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysisJ T Hartmann, L Einhorn, C R Nichols, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2011
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trialA Fléchon, D Pouessel, C Ferlay, et al.
Cancer|April 3, 2001
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcomeC Bokemeyer, J P Droz, A Horwich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)S Culine, P Kerbrat, A Kramar, et al.
Journal of the National Cancer Institute|November 22, 2001
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumorsJ T Hartmann, S D Fossa, C R Nichols, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2014
Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasiaC Even, P Pautier, P Duvillard, et al.
La Nouvelle Presse Medicale|May 30, 1981
[N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)]J Rouesse, T Tursz, T Le Chevalier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variablesJ Beyer, A Kramar, R Mandanas, et al.
Pageof 28